INTRODUCTION: Recent studies showed improved patient outcomes with endovascular treatment of acute stroke compared to medical care, including IV rtPA, alone. Seven trials have reported results, each using different clinical and imaging criteria for patient selection. We compared eligibility for different trial protocols to estimate the number of patients eligible for treatment. PATIENTS AND METHODS: Patient data were extracted from a single centre database that combined patients recruited to three clinical studies, each of which obtained both CTA and CTP within 6 h of stroke onset. The published inclusion and exclusion criteria of seven intervention trials (MR CLEAN, EXTEND-IA, ESCAPE, SWIFT-PRIME, REVASCAT, THERAPY and THRACE) were applied to determine the proportion that would be eligible for each of these studies. RESULTS: A total of 263 patients was included. Eligibility for IAT in individual trials ranged from 53% to 3% of patients; 17% were eligible for four trials and under 10% for two trials. Only three patients (1%) were eligible for all studies. The most common cause of exclusion was absence of large artery occlusion (LAO) on CTA. When applying simplified criteria requiring an ASPECT score > 6, 16% were eligible for IAT, but potentially 40% of these patients were excluded by perfusion criteria and more than half by common NIHSS thresholds. CONCLUSION: Around 15% of patients presenting within 6 h of stroke onset were potentially eligible for IAT, but clinical trial eligibility criteria have much more limited overlap than is commonly assumed and only 1% of patients fulfilled criteria for all recent trials.
INTRODUCTION: Recent studies showed improved patient outcomes with endovascular treatment of acute stroke compared to medical care, including IV rtPA, alone. Seven trials have reported results, each using different clinical and imaging criteria for patient selection. We compared eligibility for different trial protocols to estimate the number of patients eligible for treatment. PATIENTS AND METHODS: Patient data were extracted from a single centre database that combined patients recruited to three clinical studies, each of which obtained both CTA and CTP within 6 h of stroke onset. The published inclusion and exclusion criteria of seven intervention trials (MR CLEAN, EXTEND-IA, ESCAPE, SWIFT-PRIME, REVASCAT, THERAPY and THRACE) were applied to determine the proportion that would be eligible for each of these studies. RESULTS: A total of 263 patients was included. Eligibility for IAT in individual trials ranged from 53% to 3% of patients; 17% were eligible for four trials and under 10% for two trials. Only three patients (1%) were eligible for all studies. The most common cause of exclusion was absence of large artery occlusion (LAO) on CTA. When applying simplified criteria requiring an ASPECT score > 6, 16% were eligible for IAT, but potentially 40% of these patients were excluded by perfusion criteria and more than half by common NIHSS thresholds. CONCLUSION: Around 15% of patients presenting within 6 h of stroke onset were potentially eligible for IAT, but clinical trial eligibility criteria have much more limited overlap than is commonly assumed and only 1% of patients fulfilled criteria for all recent trials.
Authors: Maarten G Lansberg; Matus Straka; Stephanie Kemp; Michael Mlynash; Lawrence R Wechsler; Tudor G Jovin; Michael J Wilder; Helmi L Lutsep; Todd J Czartoski; Richard A Bernstein; Cherylee W J Chang; Steven Warach; Franz Fazekas; Manabu Inoue; Aaryani Tipirneni; Scott A Hamilton; Greg Zaharchuk; Michael P Marks; Roland Bammer; Gregory W Albers Journal: Lancet Neurol Date: 2012-09-04 Impact factor: 44.182
Authors: Charith Cooray; Klara Fekete; Robert Mikulik; Kennedy R Lees; Nils Wahlgren; Niaz Ahmed Journal: Int J Stroke Date: 2015-01-15 Impact factor: 5.266
Authors: Olvert A Berkhemer; Puck S S Fransen; Debbie Beumer; Lucie A van den Berg; Hester F Lingsma; Albert J Yoo; Wouter J Schonewille; Jan Albert Vos; Paul J Nederkoorn; Marieke J H Wermer; Marianne A A van Walderveen; Julie Staals; Jeannette Hofmeijer; Jacques A van Oostayen; Geert J Lycklama à Nijeholt; Jelis Boiten; Patrick A Brouwer; Bart J Emmer; Sebastiaan F de Bruijn; Lukas C van Dijk; L Jaap Kappelle; Rob H Lo; Ewoud J van Dijk; Joost de Vries; Paul L M de Kort; Willem Jan J van Rooij; Jan S P van den Berg; Boudewijn A A M van Hasselt; Leo A M Aerden; René J Dallinga; Marieke C Visser; Joseph C J Bot; Patrick C Vroomen; Omid Eshghi; Tobien H C M L Schreuder; Roel J J Heijboer; Koos Keizer; Alexander V Tielbeek; Heleen M den Hertog; Dick G Gerrits; Renske M van den Berg-Vos; Giorgos B Karas; Ewout W Steyerberg; H Zwenneke Flach; Henk A Marquering; Marieke E S Sprengers; Sjoerd F M Jenniskens; Ludo F M Beenen; René van den Berg; Peter J Koudstaal; Wim H van Zwam; Yvo B W E M Roos; Aad van der Lugt; Robert J van Oostenbrugge; Charles B L M Majoie; Diederik W J Dippel Journal: N Engl J Med Date: 2014-12-17 Impact factor: 91.245
Authors: Matthew B Maas; Karen L Furie; Michael H Lev; Hakan Ay; Aneesh B Singhal; David M Greer; Gordon J Harris; Elkan Halpern; Walter J Koroshetz; Wade S Smith Journal: Stroke Date: 2009-07-16 Impact factor: 7.914
Authors: James D Eastwood; Michael H Lev; Max Wintermark; Clemens Fitzek; Daniel P Barboriak; David M Delong; Ting-Yim Lee; Tarek Azhari; Michael Herzau; Vani R Chilukuri; James M Provenzale Journal: AJNR Am J Neuroradiol Date: 2003-10 Impact factor: 3.825
Authors: Mirjam R Heldner; Christoph Zubler; Heinrich P Mattle; Gerhard Schroth; Anja Weck; Marie-Luise Mono; Jan Gralla; Simon Jung; Marwan El-Koussy; Rudolf Lüdi; Xin Yan; Marcel Arnold; Christoph Ozdoba; Pasquale Mordasini; Urs Fischer Journal: Stroke Date: 2013-03-07 Impact factor: 7.914
Authors: Fahmi Al-Senani; Mohammad Salawati; Mohammed AlJohani; Matthieu Cuche; Valeska Seguel Ravest; Simon Eggington Journal: Hum Resour Health Date: 2019-12-02
Authors: Christopher I Price; Lisa Shaw; Anand Dixit; Sara Graziadio; Clare Lendrem; Dipayan Mitra; Helen Rodgers; Lou Sutcliffe; Phil White Journal: Diagn Progn Res Date: 2020-02-20
Authors: Fani Pujol-Calderón; Henrik Zetterberg; Erik Portelius; Pia Löwhagen Hendén; Alexandros Rentzos; Jan-Erik Karlsson; Kina Höglund; Kaj Blennow; Lars E Rosengren Journal: Transl Stroke Res Date: 2021-03-15 Impact factor: 6.829